Haemonetics Corporation

NYSE:HAE 주식 보고서

시가총액: US$4.1b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Haemonetics 대차 대조표 상태

재무 상태 기준 확인 2/6

Haemonetics 의 총 주주 지분은 $960.0M 이고 총 부채는 $807.8M, 이는 부채 대 자기자본 비율을 84.1% 로 가져옵니다. 총자산과 총부채는 각각 $2.2B 및 $1.2B 입니다. Haemonetics 의 EBIT는 $206.8M 이며 이자보상배율은 10.6 입니다. $180.5M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

135.1%

부채 비율

US$1.22b

부채

이자 보상 비율11.2x
현금US$346.07m
주식US$905.37m
총 부채US$1.64b
총 자산US$2.54b

최근 재무 상태 업데이트

Recent updates

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Aug 14
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Jul 18
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Jun 21

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Haemonetics: Upside Case Hinges On Blood Plasma Collection Market

Jun 11

재무 상태 분석

단기부채: HAE 의 단기 자산 ( $768.9M )이 단기 부채( $300.4M ).

장기 부채: HAE 의 단기 자산( $768.9M )은 장기 부채( $935.2M ).


부채 대 자본 내역 및 분석

부채 수준: HAE 의 순부채 대 자기자본 비율( 65.3% )은 높음으로 간주됩니다.

부채 감소: HAE 의 부채 대 자기자본 비율은 지난 5년간 53.2% 에서 84.1% 로 증가했습니다.

부채 범위: HAE 의 부채는 영업 현금 흐름 ( 11.1% )에 의해 잘 갚지 않음입니다.

이자 보장: HAE 의 부채에 대한 이자 지급EBIT( 10.6 x 적용 범위)로 잘 충당됩니다.


대차 대조표


건강한 기업 발견하기